Adicet Bio, Inc. (ACET) is a leading biotechnology company located in Menlo Park, California. It is dedicated to creating the next generation of cell therapies primarily focused on cancer treatment. Their central principle is to provide patients with superior forms of therapeutic cells, manipulated to improve their capability to target and eliminate cancer cells.
Adicet Bio, Inc., which is publicly traded on the NASDAQ under the symbol ACET, differentiates itself through its innovative science and technology. The company's operations revolve around developing "off-the-shelf" allogeneic gamma delta T cells that can be universally applicable for all patients. These improved cells are not only capable of targeting and killing cancer cells, but they can also survive within the human body, thereby providing long-term immune assistance.
Established in 2015, the company was birthed from a core understanding of the breakthrough potential of immune cell therapies for treating cancer. Since then, Adicet Bio, Inc. has built a solid reputation for innovation, reliability, and patient focus. Each day, its team of seasoned scientists, clinicians, and drug developers work tirelessly to progress the industry and transform patient care.
Adicet Bio, Inc.'s pipeline includes several investigational cell therapies for various types of cancer. Their lead product, ADI-001, an allogeneic CAR Gamma Delta T cell therapy, is currently in Phase 1 clinical trials for treating Non-Hodgkin's lymphoma. This pioneering method stands as the symbol of Adicet Bio, Inc.'s unwavering commitment to making future cancer treatments safer, more effective, and globally accessible.
The company’s partnerships with other corporations, universities, and research institutions play a vital role in its program. One notable partnership is with Regeneron Pharmaceuticals, Inc. This partnership aims to develop new immune cell therapies using Adicet's gamma delta T cell platform in combination with Regeneron's VelociSuite® technologies.
Adicet Bio, Inc. is not merely a biotechnology company but a transformer of cancer therapy. It drives scientific innovation to gear toward a future where immune cell therapy will become a mainstream form of treatment. Hence, it continues to strive to extend and improve the lives of patients worldwide, defining a new era in immunology and oncology.